We are live on ! Find out more

MannKind Corp

MNKD

Market cap $1.31B

4.06 USD

-0.03

0.73%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

4.07

+0.01

0.25%

1 day

-0.73%

5 days

-5.14%

1 month

2.78%

3 months

14.37%

6 months

23.78%

Year to date

-27.5%

1 year

-10.18%

5 years

-17.31%

10 years

8.85%

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Employees: 592

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 53.3%

Negative 13.3%

MannKind: New Approvals Majorly Increase MannKind's Prospects

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.

MannKind: New Approvals Majorly Increase MannKind's Prospects

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Q2 Earnings Call Highlights

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

MannKind Q2 Earnings Call Highlights

Zacks Investment Research

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025 Conference call and webcast today at 4:30 p.m.

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway

MannKind NASDAQ: MNKD reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability.

MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway

MannKind injection helps heart failure patients avoid ER infusions

We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.

MannKind injection helps heart failure patients avoid ER infusions

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

See News Rankings

Price charts implemented using Lightweight Charts™